Diamyd Inc

Diamyd Medical AB is a Swedish biotech company that specializes in developing precision therapies for type 1 diabetes. Their innovative products, including the antigen-specific immunotherapy Diamyd and the regenerative and immunomodulatory therapy Remygen, aim to preserve and regenerate the patients' own insulin production. With ongoing clinical trials and a focus on precision medicine, Diamyd Medical is at the forefront of advancing treatment options for individuals with autoimmune diabetes.

Utilizing a baculovirus-insect cell expression system, Diamyd Medical is also establishing a new manufacturing facility in Umeå, Sweden, for the production of recombinant GAD65, the active pharmaceutical ingredient in their investigational medicine Diamyd. Listed on Nasdaq First North Growth Market, Diamyd Medical is committed to improving the lives of the more than 463 million people worldwide who suffer from diabetes, particularly those with the autoimmune form of the disease.

Generated from the website